SCLC

SCLC
Name	Small-cell lung carcinoma
Caption	Histopathologic appearance of small-cell lung carcinoma
Field	Oncology, Pulmonology, Pathology
Symptoms	Cough, hemoptysis, dyspnea, weight loss, paraneoplastic syndromes
Onset	Typically older adults
Causes	Tobacco smoking, occupational exposures
Prognosis	Generally poor; depends on stage

SCLC

Small-cell lung carcinoma is an aggressive form of neuroendocrine lung tumor most commonly arising in the central airways. It presents with rapid growth, early metastatic spread, and frequent paraneoplastic phenomena, requiring coordinated care across oncology, thoracic surgery, radiation oncology, and palliative services. Historically linked to tobacco exposure, it continues to be a major focus of research in clinical trials and translational cancer biology.

Overview

Small-cell lung carcinoma is classified among neuroendocrine neoplasms alongside typical carcinoid, atypical carcinoid, and large-cell neuroendocrine carcinoma. Landmark institutions such as the National Cancer Institute, American Cancer Society, European Society for Medical Oncology, World Health Organization and major cancer centers including Memorial Sloan Kettering Cancer Center, Mayo Clinic, MD Anderson Cancer Center, Johns Hopkins Hospital have played key roles in defining diagnostic criteria and treatment algorithms. Seminal trials by groups like the European Organisation for Research and Treatment of Cancer and the Children's Oncology Group (for methodological parallels) influenced chemoradiotherapy standards.

Signs and symptoms

Clinical presentation often overlaps with other thoracic diseases seen at centers like Cleveland Clinic and Massachusetts General Hospital. Common local symptoms include cough, hemoptysis, chest pain, and dyspnea, and constitutional features such as weight loss and fatigue. Frequent paraneoplastic syndromes recognized in case series from institutions including Brigham and Women's Hospital and Royal Marsden Hospital include ectopic adrenocorticotropic hormone production leading to Cushingoid features, paraneoplastic encephalomyelitis associated with anti-Hu antibodies described in reports from Mayo Clinic Arizona, and Lambert–Eaton myasthenic syndrome noted in neurology departments at University of California, San Francisco. Superior vena cava syndrome and recurrent laryngeal nerve palsy occur with mediastinal involvement and have been documented in thoracic oncology case reviews from Guy's and St Thomas' NHS Foundation Trust.

Causes and pathogenesis

Tobacco smoking is the principal etiologic factor, established in epidemiologic studies by researchers at Harvard School of Public Health and cohort analyses reported by the Centers for Disease Control and Prevention. Carcinogens in cigarette smoke induce genetic alterations such as TP53 and RB1 inactivation, described in genomic studies from The Cancer Genome Atlas consortium and translational work at Wellcome Sanger Institute. Occupational exposures implicated in case–control studies include asbestos and radon, with surveillance reports by International Agency for Research on Cancer and industrial health investigations at NIOSH. Neuroendocrine differentiation involves expression of chromogranin A and synaptophysin, biomarkers validated in pathology centers such as Karolinska Institutet and Stanford University School of Medicine.

Diagnosis

Diagnostic pathways align with protocols from American Society of Clinical Oncology and the Royal College of Radiologists. Imaging typically begins with chest radiography and contrast-enhanced computed tomography reviewed by radiology departments at University College London Hospitals and Yale School of Medicine, with 18F-FDG PET/CT for staging performed in nuclear medicine units at Guy's and St Thomas' Hospital and Hôpital Pitié-Salpêtrière. Tissue diagnosis is achieved via bronchoscopy with endobronchial ultrasound-guided biopsy, transthoracic needle biopsy, or surgical biopsy, with cytopathology services at Mayo Clinic and Cleveland Clinic confirming small-cell morphology. Immunohistochemistry panels including synaptophysin, chromogranin, and CD56 are standardized by pathology groups at Royal College of Pathologists and the College of American Pathologists.

Staging and classification

Staging systems used include the Veterans Administration Lung Study Group limited/extensive schema and the tumor-node-metastasis system endorsed by the American Joint Committee on Cancer and the Union for International Cancer Control. Multidisciplinary tumor boards at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center integrate imaging, histology, and performance status to categorize disease. Molecular subtyping efforts from consortia such as The Cancer Genome Atlas and research groups at Dana-Farber Cancer Institute aim to refine classifications for targeted therapy eligibility.

Treatment

First-line therapy for limited-stage disease commonly involves concurrent platinum-etoposide chemotherapy and thoracic radiotherapy, protocols developed from randomized trials by groups like the Southwest Oncology Group and implemented at centers including MD Anderson Cancer Center. Extensive-stage disease is treated with systemic platinum-based chemotherapy, with recent practice-changing immunotherapy additions based on trials reported by AstraZeneca, Roche, and cooperative groups like the International Association for the Study of Lung Cancer. Prophylactic cranial irradiation to reduce brain metastases has been studied in randomized trials at European Organisation for Research and Treatment of Cancer and remains a consideration in selected patients. Surgical resection is rare but considered for very early-stage lesions in thoracic surgery units at University of Pittsburgh Medical Center and Mount Sinai Hospital. Palliative interventions by teams at St Christopher's Hospice and oncology services at Royal Marsden Hospital address symptom control, while clinical trials at institutions like Fred Hutchinson Cancer Center and Sloan Kettering explore novel targeted agents and antibody-drug conjugates.

Prognosis and epidemiology

Prognosis remains guarded with overall survival substantially influenced by stage, performance status, and response to therapy; survival statistics are reported by agencies such as National Cancer Institute, Office for National Statistics (UK), and cancer registries at Surveillance, Epidemiology, and End Results Program. Incidence correlates strongly with smoking prevalence trends documented by World Health Organization and national health surveys. Notable epidemiologic studies from Johns Hopkins Bloomberg School of Public Health and Columbia University Mailman School of Public Health elucidate demographic patterns, including higher incidence in older adults and historical sex differences tied to tobacco use. Ongoing research at centers like Imperial College London and Karolinska Institutet focuses on biomarkers, resistance mechanisms, and survivorship outcomes.

Category:Pulmonary neoplasms